

ARTICLE

Received 10 Jul 2015 | Accepted 23 Sep 2015 | Published 27 Oct 2015

DOI: 10.1038/ncomms9716

OPEN

Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals

Tristan Gollnest¹, Thiago Dinis de Oliveira¹, Dominique Schols², Jan Balzarini² & Chris Meier¹

The antiviral activity of nucleoside reverse transcriptase inhibitors is often limited by ineffective phosphorylation. We report on a nucleoside triphosphate (NTP) prodrug approach in which the γ -phosphate of NTPs is bioreversibly modified. A series of TriPPP_{Pro}-compounds bearing two lipophilic masking units at the γ -phosphate and d4T as a nucleoside analogue are synthesized. Successful delivery of d4TTP is demonstrated in human CD4⁺ T-lymphocyte cell extracts by an enzyme-triggered mechanism with high selectivity. In antiviral assays, the compounds are potent inhibitors of HIV-1 and HIV-2 in CD4⁺ T-cell (CEM) cultures. Highly lipophilic acyl residues lead to higher membrane permeability that results in intracellular delivery of phosphorylated metabolites in thymidine kinase-deficient CEM/TK⁻ cells with higher antiviral activity than the parent nucleoside.

¹Institute of Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany.

²Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Correspondence and requests for materials should be addressed to C.M. (email: chris.meier@chemie.uni-hamburg.de).

Over the last decades, a variety of nucleoside analogues were applied in antitumour and antiviral therapy and still play an important role to combat HIV, herpes virus, hepatitis B and hepatitis C virus infections^{1,2}. The target of these nucleoside analogue drugs is the inhibition of the virus-encoded DNA polymerases, such as the HIV reverse transcriptase (RT)^{3,4} or the HCV-encoded RNA-dependent RNA-polymerase NS5B (ref. 5), which are the key enzymes in the replication cycle of HIV and HCV, respectively. To date, eight nucleoside analogues have been approved as HIV RT inhibitors (NRTIs)⁶. NRTIs are still used as the backbone of the combined antiretroviral therapy⁷. However, the antiviral efficacy of nucleoside analogues, such as the thymidine analogue 3'-deoxy-2',3'-didehydrothymidine **1** (d4T) and 3'-deoxy-3'-azidothymidine (AZT), is dependent on the activity of host cell kinases metabolizing these nucleoside analogues into their antivirally active triphosphate forms (nucleoside triphosphates, NTPs)^{8–11}.

The stepwise transformation via the nucleoside mono- (NMP) and diphosphates (NDP) into the corresponding NTP often occurs insufficiently because of the high substrate specificity of the involved kinases (Supplementary Fig. 1). Furthermore, many nucleoside analogues have limitations such as poor biological half-lives, variable bioavailability after oral administration or selection of drug resistance, which reduce their clinical efficacy^{12,13}. To overcome these hurdles, the usage of prodrugs of the phosphorylated metabolites have been explored in the past^{14,15}.

In the case of d4T **1**, the first phosphorylation step to yield its monophosphate form **2** catalysed by the host cell enzyme thymidine kinase (TK) is metabolism-limiting because of the rather modest affinity of d4T **1** to TK as an alternative substrate and because TK activity is S-phase-dependent^{11,16,17}. However, to avoid this limitation, it is not possible to apply the charged monophosphorylated metabolite because of the high polarity and thereby extremely poor, if any, membrane permeability. The development of nucleotide prodrugs capable of delivering the monophosphorylated metabolite and thereby bypassing the intracellular activation offered advantages over the use of the corresponding nucleoside analogue^{18,19}. Moreover, lipophilic-masked NMPs such as **3** are less vulnerable to degradation by unspecific phosphatases present in the blood. This enhanced not only the plasma half-life but also enables the prodrug to be taken up by cells through passive diffusion^{20,21}. A number of successful NMP prodrug strategies were reported in the past that efficiently bypass the nucleoside kinase hurdle. These prodrug forms such as phosphoramidates and *cycloSal*-phosphate triesters of nucleoside analogues were indeed shown to deliver the NMP either by chemical or enzymatic hydrolysis in the target cells^{22–27}. In addition to NMPs also the successful delivery of acyclic nucleoside phosphonates such as cidofovir has been reported²⁸. However, all these approaches delivered the monophosphor(n)ylated forms of the nucleosides that subsequently needed further phosphorylation into the triphosphate forms by cellular kinases to inhibit their target polymerase.

However, not in all cases such NMP prodrug strategies were successful. For instance, in the case of AZT the metabolism is limited by the second conversion step, the formation of AZT-diphosphate by thymidylate kinase^{10,29}. In this case, a lipophilic prodrug that intracellularly releases the NDP would be desirable. At the same time, this would avoid toxicity caused by the parent nucleoside or the accumulation of the monophosphate form³⁰. A further example is 2',3'-dideoxy-2',3'-didehydrouridine (d4U). The parent nucleoside proved to be completely inactive against HIV replication in cell cultures. In contrast, the triphosphate form of d4U is one of the most effective inhibitors of the HIV's RT³¹.

We reported on NDP prodrugs (DiPPro-approach), which selectively released NDPs not only in phosphate buffer (pH 7.3) but for the first time also in CEM cell extracts^{32–35}. These compounds showed very good antiviral activity in TK-deficient CEM/TK⁻ cell cultures infected with HIV, proving the uptake of the compounds and the delivery of at least phosphorylated metabolites, most likely the NDP. The uptake of those compounds was achieved by two acceptor-substituted benzyloesters linked to the β -phosphate group of the NDP. The stability of the compounds correlated with the length of the aliphatic residue of the mask^{32,33}. However, we have shown that the delivery of the corresponding mono- or diphosphates from prodrug forms (such as the *cycloSal*- or DiPPro-compounds) did not improve the antiviral activity³⁴. Importantly, in the same study we have proven that d4U diphosphate was a very poor substrate for the NDP kinase, the enzyme that is generally accepted to be involved in the conversion of NDPs into their triphosphate forms. Thus, this study showed that the phosphorylation of nucleotide analogues by NDP kinase can be also rate-limiting in the activation process of a nucleoside analogue^{34,36}. As a consequence, the development of nucleoside triphosphate prodrugs would be highly interesting and desirable because this would bypass *all* steps of intracellular phosphorylation and would maximize the intracellular concentration of the ultimately bioactive NTP. Although this has been recognized before¹¹, it was also claimed that the development of prodrugs of NTP is chemically not feasible because of the low stability of such compounds³⁷. For this reason, NTPs were very rarely used as drug platforms because of their expected poor deliverability and their high sensitivity for enzymatic dephosphorylation. Thus, very few reports on potential triphosphate prodrugs have been reported^{38,39}. In addition, in the few reported examples the yields in the chemical synthesis were poor, and additionally the compounds proved hydrolytically very unstable. A difficulty that has to be taken into account in the development of NTP prodrugs is related to the energy-rich phosphate anhydride bonds within the triphosphate unit. Under physiological conditions, these linkages are only kinetically stable because of the charges present at that moiety, which prevent nucleophilic reactions that end up in the cleavage of these anhydride bonds but can be enzymatically cleaved. Interestingly, γ -modification of NTPs by esterification or replacement of the γ -phosphate group by a phosphonate moiety led to a marked increase in enzymatic stability of the triphosphate unit^{40,41}. On the other hand, complete lipophilic modification and thereby neutralization of the charges would significantly increase the reactivity of the triphosphate unit. For completeness, it should be added that the delivery challenge for NTPs has also been addressed by formulating these compounds with cationic nanogels. However, this approach still requires elaboration with respect to their toxicity, immunogenicity and pharmacokinetics^{42,43}.

Here we disclose the development of a novel prodrug concept for NTPs that releases directly NTPs with high selectivity by an enzyme-triggered mechanism and thus allows the bypass of *all* phosphorylation steps normally needed for the activation of a nucleoside analogue (Supplementary Fig. 2). To achieve this goal, the γ -phosphate group of a NTP was modified by esterification with acyloxybenzyl moieties (TriPPPro-compounds). By fine-tuning the lipophilicity through the use of different acyl esters the chemical stability also proved controllable so that the polarity caused by the remaining charges at the α - and β -phosphates could be efficiently compensated.

The cleavage of the prodrug moieties is initiated by an enzymatic hydrolysis of the phenolic acyl-ester. This reaction leads to a spontaneous cleavage of the benzyl C–O bond forming

first a monomasked intermediate of the NTPs. This process is repeated for the second mask so that finally the NTP is formed³². Lipophilic aliphatic esters have proven to be suitable for prodrugs to allow entering the cell independently of nucleoside transporters but to enable removal of the lipophilic prodrug moieties by cellular esterases/lipases⁴⁴. Moreover, fatty-acid esters are known to be taken up by the mononuclear phagocyte system. These cells are important in the pathogenesis of AIDS and are considered to be reservoirs for HIV particles^{45,46}.

We report on the synthesis of NTP prodrugs **3** bearing two identical 4-alkanoyloxybenzyl- (**a–k**), 4-alkoxycarbonyloxybenzyl- (**l–n**) and 4-aminocarbonyloxybenzyl groups (**o–q**), their hydrolysis properties in different media, the hydrolysis mechanism, primer extension assays and their anti-HIV activity. In addition, the synthesis of the monomasked (4-alkyloxybenzyl)-d4TTPs **4a,e,j** is reported. As a model nucleoside analogue, d4T **1** was used to allow a comparison of the TriPPPPro-compounds **3** with the DiPPro-compounds.

Results

Synthesis of TriPPPPro-d4T triphosphate prodrugs 4. For the synthesis of TriPPPPro-d4TTP prodrugs **3** a convergent strategy using a dicyanoimidazol (DCI)-mediated coupling of an appropriate phosphoramidite **5** and d4TDP **6** to form the energetically rich pyrophosphate moiety in the last step was performed (Fig. 1). First, d4T **1** was prepared in good overall yields according to a three-step protocol reported by Horwitz⁴⁷. From that compound, d4TDP **6** was prepared by applying the *cycloSal* technique (55% yield) because it has been reported that acceptor-substituted *cycloSal* nucleotides gave access to diphosphorylated compounds by using tetra-*n*-butylammonium phosphate as a nucleophile⁴⁸. Therefore, the 5-chloro-substituted *cycloSal*-phosphate triester **7** was synthesized starting from d4T **1** with 5-chlorosaligenylchlorophosphite **8** followed by oxidation with *tert*-butylhydroperoxide to give the product **7** as a mixture of two diastereomers in high yields.

Despite its very difficult chromatographic properties, the resulting crude (*n*-Bu)₄N⁺-salt **6** was purified by automatic RP-18 flash chromatography without additional ion exchange.

The hygroscopic tetra-*n*-butylammonium salt form of d4TDP **6** was co-evaporated in dimethylformamide (DMF) and dried in high vacuum before the coupling reaction to ensure dry reaction conditions. The use of tetra-*n*-butylammonium counterions afforded a higher reactivity and better solubility in organic solvents. D4TDP **6** was then reacted with a series of phosphoramidites **5** in a very fast DCI-mediated coupling reaction and was oxidized^{32,33}.

Inspired by recently published biodegradable linear polymers that were degraded by an acid-induced cascade reaction, we also synthesized carbamate derivatives **3o–q** (ref. 49). In this case, 4-hydroxybenzyl alcohol **10** was first protected with *tert*-butyldimethylsilyl chloride to give compound **11** followed by an esterification using 4-nitrophenyl chloroformate. To trap the excess of the chloroformate, triethylene glycol monomethyl ether was added⁴⁹. The obtained carbonate **12** was then converted with *t*-Boc-protected dimethylethylenediamine **13** and after acid-catalysed cleavage of both protecting groups the methylcarbamate **14** was isolated in 98% yield. Finally, phenylcarbamates **15** were synthesized starting from **14** in an one-pot reaction including tetramethylsilane (TMS) protection, coupling with the corresponding acyl chloroformates **16** and desilylation in a yield of up to 59% (Fig. 2).

The 4-hydroxybenzyl alcohols bearing acyl-ester groups at the phenol and the carbamates were converted into phosphoramidites **5** in high yields as published before^{32,33}. Finally, d4TDP **6** was mixed with 1.7 equivalents (eq.) of a corresponding phosphoramidite **5** and co-evaporated with acetonitrile. Then, the mixture was dissolved in a minimum of acetonitrile because achieving a high concentration was crucial for the success of the coupling reaction. In case of compounds with long acyl residues ($R \geq C_{11}H_{23}$), tetrahydrofuran (THF) was added to accomplish complete solubility of the reagents. In some cases, the conversion of d4TDP **6** was not complete. In these cases, all volatile components were removed *in vacuum*, the residue was redissolved and further 1.0 eq. of the phosphoramidite **5** and 0.8 eq. of DCI were added. After another minute of stirring, the reaction mixture was oxidized. After oxidation the quantitative consumption of d4TDP **6** was confirmed using high-performance




Figure 1 | Reagents and conditions. (i) Triethylamine, THF, 0 °C–rt, 20 h; (ii) **1**, 5-chlorosaligenylchlorophosphite **8**, *N,N*-diisopropylethylamine, CH₃CN, –20 °C–rt, 3 h, **2**, *t*-BuOOH in *n*-decane, 0 °C–rt, 30 min; (iii) (H₂PO₄)Bu₄N, DMF, rt, 20 h; (iv) **1**, DCI, CH₃CN, rt, 1 min, **2**, *t*-BuOOH in *n*-decane, 0 °C–rt, 15 min.




Figure 2 | Reagents and conditions. (i) TBDMS-Cl, imidazole, CH_2Cl_2 , rt, 2 h; (ii) **1**, 4-nitrophenyl chloroformate, triethylamine, CH_2Cl_2 , rt, 16 h, **2**, triethylene glycol monomethyl ether, rt, 20 min; (iii) Boc_2O , 0°C -rt, 20 h; (iv) **1**, 4-DMAP, diisopropylethylamine, toluene, rt, 16 h, **2**, TFA/ CH_2Cl_2 , rt, 0.5 h; (v) **1**, TMS-Cl, imidazole, THF, 0°C -rt, 2 h, **2**, triethylamine, 0°C -rt, 1.5 h, **3**, 1% HCl (12 M) in EtOH, rt, 1 h.




Figure 3 | Reagents and conditions. (i) **1**, diisopropylethylamine, CH_3CN , -20°C -rt, 1 h, **2**, oxone, $\text{H}_2\text{O}/\text{CH}_3\text{CN}$, rt, 30 min; (ii) bis(tetra-*n*-butyl)ammonium-d4TDP **6**, DMF, rt, 3 h.

liquid chromatography (HPLC; Supplementary Fig. 3). Next, the solvent was removed *in vacuo* and the crude product was purified with RP-18 chromatography using gradients of water/acetonitrile or water/THF as eluents. For compounds **3a-f**, **1-n**, **o-q** the tetra-*n*-butylammonium ions were exchanged by ammonium ions using Dowex 50WX8 and the chromatography was repeated.

Synthesis of monomasked triphosphate prodrugs 4. In addition to the TriPPPro-compounds **3**, the monomasked acyloxybenzyl-NTP derivatives **4** were synthesized as well (Fig. 3). Such

monoesterified substances were described by others as potential triphosphate prodrugs^{38,39,50}. Several synthesis routes mainly based on DCC-activated coupling were published. In our recent studies with DiPPPro-prodrugs, we isolated such monoesterified compounds by simple hydrolysis³³.

An efficient access to such compounds was developed in this study. The monoesterified NTPs were prepared starting from 4-acyloxybenzyl alcohol **9** and its conversion into the 5-nitro-*cycloSal*-triester **17**. Despite the high reactivity of this compound, the purification by preparative thin-layer chromatography (TLC) was successful. The benzyl-(5-nitro-*cycloSal*)-phosphate triesters **17** were obtained in high yields (up to

89%). Next, triesters **17** gave the monomasked acyloxybenzyl-d4TTPs **4** in yields of 26–30% by the addition of d4TDP **6**.

Stability studies. The TriPPPPro-d4TTP prodrugs **3** and the intermediates **4** were incubated in PBS (25 mM, pH 7.3), or were exposed to pig liver esterase (PLE) in PBS and to human CD₄⁺ T-lymphocyte cell extracts to study their stability and the product distribution. The hydrolysis mixtures were analysed by means of analytical RP-18-HPLC. The calculated half-lives (Table 1) were determined for the first removal of one masking unit ($t_{1/2}(1)$) to yield the intermediate **4** and the second hydrolysis step ($t_{1/2}(2)$) to give the triphosphate **19**.

Chemical stability in PBS at pH 7.3. In PBS, the stability of TriPPPPro-d4TTP prodrugs **3a–h, l–n** increased with increasing alkyl chain lengths (Table 1). However, the half-lives of more lipophilic compounds **3i–k** decreased because of altered solubility behaviour or micelle formation. The half-lives of the intermediates **4** were always considerably higher than those of their precursors **3** because of the increase in charges leading to repulsive interaction with an incoming nucleophile. Moreover, formation of the three nucleotide forms **2**, **6** and **19** were observed (Supplementary Fig. 4).

Hydrolysis study using esterase. Next, we examined the enzymatic stability of prodrugs **3a–n** by incubation with PLE in PBS, pH 7.3. The cleavage of the masking units for **3b–g** occurred much faster than that in PBS, demonstrating a significant contribution of the enzymatic cleavage (Table 1). As observed in the chemical hydrolysis studies, the cleavage of the second masking group proceeded much slower. According to the substrate specificity of PLE we determined the lowest half-lives for **3c–f** and **3m**. Shorter as well as longer alkyl residues in the ester moiety of the masking group led to increased half-lives. In addition, d4TTP

19 was delivered by enzymatic activation of **3a–n** but was also found to be the sole metabolite from **4a, e, j** as long as the enzymatic cleavage occurred rapidly (Supplementary Fig. 5). The carbamate-functionalized prodrugs **3o–q** were not substrates for PLE, as expected.

To confirm the prodrug concept and thus the direct successful release of the biologically active triphosphate metabolite, the prodrug **3e** was exposed to PLE and the hydrolysis monitored with RP-18-HPLC. After complete consumption of **3e** as well as its intermediate **4e** the solvents were removed. For the template/primer extension assay (Fig. 4a), HIV RT was incubated with the PLE hydrolysate as such (T*) or with the PLE hydrolysate in the additional presence of dCTP (T*, C), or dCTP + dGTP (T*, C, G) or all natural 2'-deoxynucleotides (N*). Interestingly, an immediate DNA chain termination was observed after incorporation of d4TMP **2** (derived from the incoming d4TTP **19** that was released from the prodrug by PLE), while the control reaction containing all four natural NTPs in the absence of the PLE hydrolysate (N) showed full extension of the primer (Fig. 4a). In addition, TriPPPPro-TTP **3r** was synthesized (Fig. 5) and also investigated in the same way. As expected, the template/primer extension assay showed efficient DNA elongation (Fig. 4b). The T* lysate resulted in termination of the polymerization because of the lack of the next complementary nucleotide (dCTP; position 26 nt), whereas the reaction proceeded till position 28 nt in the presence of both T* and dCTP (T*, C). The primer could be fully extended till 30 nt when T* was added in the presence of dCTP and dGTP, as also the N* and N samples could.

Hydrolysis in cell extracts. The hydrolysis of the TriPPPPro-compounds **3** was further investigated in human CD₄⁺ T-lymphocyte CEM cell extracts. Again, the half-lives of the prodrugs **3a–n** correlated well with chain length and were significantly lower than the half-lives in PBS buffer (Table 1). Thus, an enzymatic cleavage reaction took place as described above for the PLE studies. Furthermore, we observed the formation of the corresponding intermediates **4a–n** that had lower half-lives than their parent prodrugs. This assumption was proven by hydrolysis of the synthesized intermediates **4a, e, j**. In contrast to hydrolysis studies with PLE, in addition to d4TTP **19** d4TDP **6** was also detected as a major component in the CEM cell extracts most probably because of the presence of hydrolytic enzymes such as phosphatases and esterases (Supplementary Fig. 6).

The formation of d4TDP **6** was clearly not a result of unselective cleavage of the prodrug **3**. Investigations in cell

Table 1 | Hydrolysis half-lives of TriPPPPro-d4TTPs **3 and monoesterified d4TTPs **4** in different media.**

Compd	R	PBS, pH = 7.3 (h)		PLE (h)		CEM (h)
		$t_{1/2}(1)^*$	$t_{1/2}(2)^{\ddagger}$	$t_{1/2}(1)^*$	$t_{1/2}(2)^{\ddagger}$	
3a	CH ₃	18	75	1.9	71	0.050
3b	C ₂ H ₅	17	150	0.42	33	0.12
3c	C ₄ H ₉	22	270	0.063	7.7	0.43
3d	C ₆ H ₁₃	26	350	0.013	1.6	0.98
3e	C ₈ H ₁₇	52	390	0.013	1.6	2.5
3f	C ₉ H ₁₉	44	350	0.082	3.0	2.8
3g	C ₁₁ H ₂₃	68	410	0.95	8.3	2.2
3h	C ₁₃ H ₂₇	90	355	30	n.d. [‡]	4.6
3i	C ₁₅ H ₃₁	73	462	33	n.d. [‡]	5.3
3j	C ₁₇ H ₃₅	50	583	37	n.d. [‡]	13
3k	C ₁₇ H ₃₃ (8Z)	27	92	42	n.d. [‡]	4.3
3l	OCH ₃	24	200	3.8	177	0.97
3m	OC ₈ H ₁₇	82	590	0.12	17	2.6
3n	OC ₁₁ H ₂₃	99	631	44	n.d. [‡]	3.0
3o	NCH ₃ (C ₉ H ₁₉ NO ₂)	27	n.d. [‡]	n.d. [§]	n.d. [§]	n.d. [‡]
3p	NCH ₃ (C ₁₃ H ₂₇ NO ₂)	48	n.d. [‡]	n.d. [§]	n.d. [§]	5.6
3q	NCH ₃ (C ₁₇ H ₃₅ NO ₂)	48	n.d. [‡]	n.d. [§]	n.d. [§]	n.d. [‡]
4a	CH ₃	n.a.	95	n.a.	108	0.040
4e	C ₈ H ₁₇	n.a.	237	n.a.	1.5	1.8
4j	C ₁₇ H ₃₅	n.a.	637	n.a.	57	4.6

*Half-lives of **3**.

†Half-lives of **4**.

‡Not determined.

§No substrate for enzyme.

||Not available.




Figure 4 | Primer extension assays with HIV reverse transcriptase.

(a) PLE hydrolysate based on TriPPPPro-d4TTP **3e** (T*); dCTP; dGTP; all natural triphosphates (N); dATP, dCTP, dGTP and the hydrolysate of **3e** (N*). (b) PLE hydrolysate based on TriPPPPro-compound **3r** (T*); dCTP; dGTP; all natural triphosphates (N); dATP, dCTP, dGTP and the hydrolysate of **3r** (N*). nt: nucleotide, length of primer.




Figure 5 | Reagents and conditions. (i) **1**. TBDMSCl, pyridine, rt, 20 h, **2**. Ac₂O, rt, 5 h, **3**. TBAF, THF, 0 °C, 1.5 h; (ii) **1**. 5-chlorosaligenylchlorophosphite **8**, *N,N*-diisopropylethylamine, CH₃CN, 0 °C-rt, 3 h, **2**. *t*-BuOOH in *n*-decane, 0 °C, 20 min; (iii) **1**. (H₂PO₄)Bu₄N, DMF, rt, 20 h, **2**. MeOH/H₂O/Bu₄NOH (7:3:1), rt, 17 h; (iv) **1**. **5e**, DCl, CH₃CN, rt, 1 min; **2**. *t*-BuOOH in *n*-decane, 0 °C-rt, 15 min.

Table 2 | Antiviral activity and cytotoxicity of TriPPPPro-d4TTPs 3 in comparison with the parent nucleoside d4T 1.

Compd	EC ₅₀ (μM) [*]			CC ₅₀ (μM) [†]
	CEM		CEM/TK ⁻	CEM
	HIV-1	HIV-2	HIV-2	
3a	0.43 ± 0.25	0.72 ± 0.16	> 10	63 ± 2
3b	0.46 ± 0.21	1.16 ± 0.15	> 10	57 ± 6
3c	0.40 ± 0.00	1.05 ± 0.30	> 10	58 ± 3
3d	0.36 ± 0.06	0.94 ± 0.16	10 ± 0.00	74 ± 2
3e	0.31 ± 0.01	0.62 ± 0.30	2.26 ± 1.03	52 ± 1
3f	0.25 ± 0.07	0.33 ± 0.03	0.50 ± 0.14	34 ± 5
3g	0.21 ± 0.01	0.27 ± 0.06	0.72 ± 0.16	26 ± 0
3h	0.50 ± 0.14	1.10 ± 0.23	1.63 ± 0.52	28 ± 7
3i	0.62 ± 0.30	0.66 ± 0.08	0.72 ± 0.16	61 ± 3
3j	0.17 ± 0.00	0.31 ± 0.00	0.28 ± 0.04	29 ± 9
3k	0.30 ± 0.01	0.47 ± 0.10	0.93 ± 0.47	25 ± 1
3l	0.40 ± 0.00	0.92 ± 0.12	> 10	16 ± 1
3m	0.36 ± 0.06	0.47 ± 0.10	1.26 ± 0.00	51 ± 5
3n	0.50 ± 0.14	0.69 ± 0.21	1.26 ± 0.00	41 ± 12
d4T	0.33 ± 0.11	0.89 ± 0.00	150 ± 9	79 ± 3

^{*}Antiviral activity in CD4⁺ T-lymphocytes: 50% effective concentration; values are the mean ± s.d. of *n* = 2-3 independent experiments.

[†]Cytotoxicity: 50% cytostatic concentration or compound concentration required to inhibit CD4⁺ T-cell (CEM) proliferation by 50%; values are the mean ± s.d. of *n* = 2-3 independent experiments.

extracts starting from d4TTP **19** led to a rapid degradation (*t*_{1/2} = 0.63 h). For this reason d4TDP **6** (*t*_{1/2} = 59 h) accumulated under these conditions. On the other hand, only very small amounts of d4TMP **2** were formed. Nevertheless, it was proven that the triphosphate of d4T **19** was successfully released in biological media such as CD4⁺ T-lymphocyte extracts.

Antiviral evaluation. TriPPPPro-compounds **3a-n** were evaluated for their ability to inhibit the replication of HIV. For this purpose, HIV-1- or HIV-2-infected wild-type CEM/0 as well as mutant TK-deficient CEM cell cultures (CEM/TK⁻) were treated with the prodrugs **3**. As can be seen in Table 1, all compounds showed virtually similar activities against HIV-1 and HIV-2 as the parent nucleoside d4T **1**. A somewhat increased antiviral activity with increasing lipophilicity resulting from their advantageous permeability was observed. In addition, all prodrugs with R ≥ C₈H₁₇ were also highly potent in CEM/TK⁻ cells, whereas d4T **1** lacked

relevant anti-HIV activity as expected in this TK-deficient cell model (EC₅₀:150 μM). It should also be noticed that none of the prodrugs **3** were endowed with a significantly higher cytotoxicity than the parent d4T **1** compound (Table 2).

Discussion

We reported on the first successful direct intracellular delivery of NTPs using prodrug technology. D4T triphosphate prodrugs **3a-q** were prepared via a convergent route using phosphoramidite chemistry (Fig. 1). Despite complete and selective conversion, TriPPPPro-NTP prodrugs **3** were obtained in yields between 27 and 66%. We assumed that the loss in yield may be the result of a cleavage of the β- and γ-phosphate anhydride bond of the prodrugs during work-up. This assumption was supported by the detection of d4TDP **6** and the bis(benzyl)phosphate diester after chromatography. Alternative purification methods such as extraction and precipitation were investigated but proved to be

inefficient. Nevertheless, by this method a large number of TriPPPPro-d4TTPs **3** bearing various acyloxybenzyl-masking units were obtained. Moreover, this synthesis strategy also showed to be applicable to the synthesis of TriPPPPro-compounds bearing other pyrimidine or purine nucleoside analogues. In addition, the intermediates **4a,e,j** were synthesized using the *cycloSal* method and were obtained in moderate chemical yields. This method, which is based on the *cycloSal* strategy, is a reliable method for the synthesis of polyphosphate diesters comprising esters at both ends of the polyphosphate group (Fig. 3)^{48,51,52}.

In general, three reactions should be considered in the hydrolysis pathways of TriPPPPro-nucleotide prodrugs **3**. First, the designed pathway yielding the NTP; second, a concurrent reaction that involved a nucleophilic reaction at the γ -phosphate leading to the formation of d4TDP **6**; and third, a nucleophilic reaction at the β -phosphate that would lead to d4TMP **2**. Figure 6 summarizes all three possible hydrolysis pathways leading to the different phosphorylated nucleotide species. As shown in Fig. 6, to release d4TTP **19** two successive cleavage processes were necessary (path A). Thus, in addition to hydrolysis pathway A, also a reaction at the γ - and β -phosphate groups took place as side-reactions. Owing to the presence of a second energetically rich pyrophosphate bond, but despite its additional negative charge, the half-lives were found to be lower than those published recently for the DiPPPPro-d4TDPs³³. However, the triphosphate **19** was the predominant product formed (Supplementary Fig. 4). Moreover, after the starting material **3e** was completely consumed, there was no further increase in the amounts of d4TMP **2** and d4TDP **6**, which again points to the fact that the intermediate selectively delivers the triphosphate while the mono- and the diphosphate are formed from the starting

TriPPPPro-compounds only. A comparable behaviour has also been observed for the DiPPPPro-compounds³³.

In contrast, for the carbamate derivatives **3o-q** the cleavage of the masking groups occurred only once leading to the intermediates **4o-q**. Therefore, it was concluded that the delivery mechanism should be different as compared with the ester-bearing masking groups. Owing to the highly stable carbamate functions present in the masking group, the first masking group cannot be cleaved by the original mechanism that involves a cleavage within the ester/carbamate residue. To gain more insights into this, a hydrolysis experiment of derivative **3o** was conducted in ¹⁸O-labelled water to yield **4o**. Surprisingly, the ¹⁸O-label was found in the cleaved benzyl-alcohol and not at the phosphate, which was convincingly confirmed using mass spectrometry (Supplementary Fig. 7). Two different interpretations are possible for this result: (i) a S_N1-type reaction took place forming a benzyl cation and the monomasked NTP intermediate **4**. The cation is then trapped by addition of water or (ii) a S_N2-type reaction took place instead in which the labelled water displaces the monomasked NTP intermediate **4** (Fig. 6, hydrolysis pathway A₂). In addition to hydrolysis in PBS, pH 7.3, **4p** was hydrolysed under slightly acidic conditions (pH 6.0), although in comparison with the physiological pH conditions no difference in its hydrolysis behaviour was observed. Because of the very long hydrolysis time periods, a cleavage of the glycosidic bond in d4T **1** resulted in the appearance of the nucleobase thymine. The amount doubles every 63 h; however, this aspect has not been further considered in these investigations because it was irrelevant in the enzyme or cell extract incubations and in the case of other nucleoside analogues.

Finally, a very important result from the studies conducted with the monomasked intermediates **4a,e,j** was the finding that exclusively d4TTP **19** was formed from these compounds. In addition, the hydrolysis studies conducted in the presence of PLE clearly led to the selective formation of two different NTPs (d4TTP and TTP) from the corresponding prodrug forms.

In conclusion, because of a successful cell membrane passage of the TriPPPPro-compounds **3** and subsequent intracellular enzymatic hydrolysis, which led to the direct intracellular formation of phosphorylated d4T metabolites such as d4TTP **19** or at least d4TDP **6**, marked anti-HIV activity in CEM/TK⁻ cell cultures was observed while the parent nucleoside d4T **1** lacked significant activity in this cell assay. Thus, although the TriPPPPro-compounds are still charged at the phosphate groups, obviously the modification at the γ -phosphate group by lipophilic, bioreversible moieties gives the molecule sufficient lipophilicity to penetrate the cell membrane. To the best of our knowledge, we provided the first direct proof of the successful application of masked triphosphates that obviously are able to efficiently enter the cells and to directly deliver a higher phosphate derivative, most likely d4TTP **19**. Because the concept should be generally applicable to natural nucleosides and a broad variety of nucleoside analogues, a novel way to deliver the corresponding bioactive triphosphate form of these nucleosides without any need for further enzymatically catalysed phosphorylation has been discovered. This concept seems to be very interesting for application with nucleoside analogues that show severe limitations in their activation to give the corresponding NTPs. Moreover, we are convinced that this approach is not limited to HIV treatment but can also be used for other viral targets and cancer and can also be used as a delivery for non-natural NTPs as biochemical tools in Chemical Biology approaches.




Figure 6 | Chemical hydrolysis pathways for TriPPPPro-d4TTPs **3.**

A₁₊₂ delivery of d4TTP **19**; B release of d4TDP **6** by cleavage of the phosphoanhydride bond between β - and γ -phosphate; C release of d4TMP **2** by cleavage of phosphoanhydride bond between α - and β -phosphate.

Methods

General. All reactions were carried out under dry conditions and at room temperature. *Solvents and reagents:* Acetonitrile, THF and DMF were purchased from Acros Organics (Extra Dry over molecular sieves) and dried with activated

molecular sieves. Triethylamine and *N,N*-diisopropylethylamine were refluxed over CaH₂ for 3 days and distilled under nitrogen. 5-Chlorosalicylchlorophosphite **8** and 5-nitrosalicylchlorophosphite **18** were synthesized according to the literature and **8** freshly distilled before use⁴⁸. All further reagents commercially available were used as received. **Thin-layer chromatography**: For TLC Macherey–Nagel pre-coated TLC sheets Alugram Xtra SIL G/UV254 were used; sugar-containing compounds were visualized with sugar spray reagent (4-methoxybenzaldehyde/EtOH/concentrated sulphuric acid/glacial acetic acid in ratio 5/90/5/0.1 v/v) and phosphate-containing compounds with ammonium molybdate solution (1 g (NH₄)₆Mo₇O₂₄ 4 H₂O in 7 ml semiconcentrated nitric acid and 13 ml water) followed by tin(II)chloride solution (0.1 g SnCl₂ 2 H₂O in 20 ml 0.5 mol l⁻¹ hydrochloric acid). **Preparative chromatography**: The preparative TLCs were accomplished with a chromatotron (Harrison Research, Model 7,924T) using glass plates coated with 2 or 4 mm layers of Merck 60 PF₂₅₄ silica gel. **Column chromatography**: Normal phase column chromatography was performed with Macherey–Nagel silica gel 60 M (0.04–0.063 mm). **Automatic RP-18 chromatography**: For reverse-phase chromatography, an Intershim Puriflash 430 in combination with Chromabond Flash RS40 C₁₈ec was used. **High-performance liquid chromatography**: HPLC was required for analytical studies and monitoring reactions. It was performed using a VWR-Hitachi LaChromElite HPLC system (L-2130, L-2200, L-2455) and EzChromElite software, equipped with a Nucleodur 100–5 C₁₈ec or Nucleodur 100–5 C₈ec (Macherey–Nagel). Acetonitrile for HPLC was obtained from VWR (HPLC grade) and ultrapure water using Sartorius Aurium pro (Sartopore 0.2 µm, UV detector). Tetra-*n*-butylammonium acetate solution (2 mM; TBAA, pH 6.3) or 10 mM triethylammonium acetate (TEAA, pH 6.2) were used for buffering. **Method A**: Nucleodur 100–5 C₁₈ec; 0–20 min: TBAA buffer/acetonitrile gradient (5–80%); 20–30 min: buffer/acetonitrile (80%); 30–33 min: buffer/acetonitrile (80–5%); 33–38 min: buffer/acetonitrile (5%); flow: 1 ml min⁻¹. **Method B**: Nucleodur 100–5 C₁₈ec; 0–20 min: TEAA buffer/acetonitrile gradient (5–90%); 20–30 min: buffer/acetonitrile (90%); 30–33 min: buffer/acetonitrile (90–5%); 33–38 min: buffer/acetonitrile (5%); flow: 1 ml min⁻¹. **Method C**: Nucleodur 100–5 C₈ec; 0–25 min: TBAA buffer/acetonitrile gradient (5–80%); 25–30 min: buffer/acetonitrile (80%); 30–33 min: buffer/acetonitrile (80–5%); 33–38 min: buffer/acetonitrile (5%); flow: 1 ml min⁻¹.

Nuclear Magnetic Resonance: NMR spectra were recorded at room temperature in an automation mode with a Varian Gemini 2000BB, Bruker Fourier 300, Bruker AMX 400, Bruker DRX 500 or Bruker Avance 600. All ¹H- and ¹³C-NMR chemical shifts (δ) are quoted in parts per million (p.p.m.) downfield from TMS and calibrated on solvent signal. The ³¹P-NMR chemical shifts (proton decoupled) are also quoted in p.p.m. using phosphoric acid as the external standard. **Mass spectrometry**: high resolution mass spectrometry (HRMS) and electrospray ionization (ESI) mass spectra were acquired with a VG Analytical Finnigan ThermoQuest MAT 95 XL spectrometer. MALDI measurements (matrix: 9-aminoacridine (9AA)) were performed with a Bruker UltrafleXtreme spectrometer. **Infrared spectroscopy**: IR spectra were recorded on a Bruker Alpha P FT-IR at room temperature in the range of 400–4,000 cm⁻¹.

General procedure A: preparation of 4-acyloxybenzyl alcohols 9. 4-Hydroxybenzyl alcohol **10** (1.1 eq.) and triethylamine (1.0 eq.) in THF were cooled down to 0 °C. The corresponding acyl chloride (1.0 eq.) in THF was added dropwise and the mixture stirred for 1–2 h. The precipitate was removed by filtration and the solvent evaporated in vacuum. The residue was diluted with CH₂Cl₂ and washed once with saturated sodium bicarbonate solution and once with water. The organic layer was dried with Na₂SO₄ and the solvent was removed in vacuum. The crude material was purified using column chromatography to give compound **9**.

The syntheses and characterization of 4-(hydroxymethyl)phenylalkanoates **9a-k** were described previously³³.

4-(Hydroxymethyl)phenylmethylcarbonate 9l. General procedure A with 4.0 g 4-hydroxybenzyl alcohol **10** (33 mmol, 1.1 eq.), 4.1 ml triethylamine (3.0 g, 30 mmol, 1.0 eq.) dissolved in 35 ml THF and dropwise addition of 2.3 ml methyl chloroformate (2.8 g, 30 mmol, 1.0 eq.) in 20 ml THF at 0 °C. Reaction time was 1.5 h at room temperature (rt). Column chromatography (petroleum ether 50–70/ethyl acetate 4:3 v/v). Yield: 4.6 g (25 mmol, 85%) colourless oil. TLC (petroleum ether 50–70/ethyl acetate 3:2 v/v): R_f = 0.35; ¹H-NMR (400 MHz, dimethylsulphoxide (DMSO-*d*₆): δ 7.39–7.31 (*m*, 2H), 7.20–7.13 (*m*, 2H), 5.22 (*t*, *J* = 5.7 Hz, 1H), 4.50 (*d*, *J* = 5.8 Hz, 2H), 3.82 (*s*, 3H); ¹³C-NMR (101 MHz, DMSO-*d*₆): δ 153.7, 149.5, 140.5, 127.5, 121.4, 62.3, 55.4; infrared red (IR): 3,375, 2,959, 2,873, 1,758, 1,254, 1,210 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₉H₁₀O₄, 205.0471; found, 205.0337.

4-(Hydroxymethyl)phenyloctylcarbonate 9m. General procedure A with 3.1 g 4-hydroxybenzyl alcohol **10** (25 mmol, 1.1 eq.), 3.1 ml triethylamine (2.3 g, 23 mmol, 1.0 eq.) dissolved in 35 ml THF and dropwise addition of 4.4 ml octyl chloroformate (4.4 g, 23 mmol, 1.0 eq.) in 20 ml THF at 0 °C. Reaction time was 1.5 h at rt. Column chromatography (petroleum ether 50–70/ethyl acetate 4:3 v/v). Yield: 5.3 g (19 mmol, 84%) colourless oil. TLC (PE/EE 3:1 v/v): R_f = 0.45; ¹H-NMR (300 MHz, DMSO-*d*₆): δ 7.39–7.31 (*m*, 2H), 7.21–7.12 (*m*, 2H), 5.22 (*t*, *J* = 5.7 Hz, 1H), 4.49 (*d*, *J* = 5.7 Hz, 2H), 4.18 (*t*, ³J_{HH} = 6.6 Hz, 2H), 1.72–1.58 (*m*, 2H),

1.41–1.18 (*m*, 10H), 0.87 (*t*, *J* = 6.7 Hz, 3H); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ 153.2, 149.5, 140.4, 127.5, 120.8, 68.5, 62.3, 31.2, 28.6, 28.0, 25.2, 22.1, 28.6, 14.0; IR: 3,377, 2,955, 2,856, 1,758, 1,247, 1,210 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₁₆H₂₄O₄, 303.1567; found, 303.1568.

4-(Hydroxymethyl)phenyldodecylcarbonate 9n. General procedure A with 4.1 g 4-hydroxybenzyl alcohol **10** (33 mmol, 1.1 eq.), 4.0 ml triethylamine (2.9 g, 30 mmol, 1.0 eq.) dissolved in 40 ml THF and dropwise addition of 8.1 ml dodecyl chloroformate (7.5 g, 30 mmol, 1.0 eq.) in 20 ml THF at 0 °C. Reaction time was 1.5 h at rt. Column chromatography (petroleum ether (PE) 50–70/ethyl acetate (EE) 4:1 v/v). Yield: 7.7 g (23 mmol, 76%) colourless oil. TLC (PE/EE 3:1 v/v): R_f = 0.48; ¹H-NMR (300 MHz, CDCl₃): δ 7.42–7.33 (*m*, 2H), 7.21–7.12 (*m*, 2H), 4.68 (*s*, 2H), 4.24 (*t*, *J* = 6.7 Hz, 2H), 1.81–1.69 (*m*, 2H), 1.47–1.19 (*m*, 18H), 0.88 (*t*, *J* = 6.7 Hz, 3H); ¹³C-NMR (75 MHz, CDCl₃): δ 153.9, 150.7, 138.8, 128.2, 121.1, 69.2, 64.8, 32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 28.7, 25.8, 22.8, 28.6, 14.3; IR: 3,355, 2,917, 2,848, 1,747, 1,273 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₂₀H₃₄O₄, 359.2193; found, 359.2195.

4-(((tert-Butyldimethylsilyloxy)methyl)phenol 11. 4-Hydroxybenzyl alcohol **10** (5.1 g; 41 mmol, 1.0 eq.), dissolved in 40 ml DMF, was converted with 6.8 g *tert*-butyldimethylsilyl chloride (45 mmol, 1.1 eq.) and 6.1 g imidazole (89 mmol, 2.2 eq.). After 17 h the solvent was removed by evaporation. The crude product was dissolved in CH₂Cl₂ and washed with 0.1 M HCl. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed by evaporation. Column chromatography (petroleum ether 50–70/ethyl acetate 6:1 v/v). Yield: 7.9 g (33 mmol, 81%) colourless oil. TLC (PE/EE 4:1 v/v): R_f = 0.34; ¹H-NMR (300 MHz, DMSO-*d*₆): δ 9.28 (*s*, 1H), 7.12–7.06 (*m*, 2H), 6.74–6.68 (*m*, 2H), 4.56 (*s*, 2H), 0.87 (*s*, 9H), 0.04 (*s*, 6H); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ 139.2, 131.6, 127.5, 114.6, 64.0, 25.6, 17.6, –5.4; IR: 3,355, 2,954, 2,857, 1,707, 1,515 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₁₃H₂₂O₂Si, 261.1287; found, 261.1285.

4-(((tert-Butyldimethylsilyloxy)methyl)phenyl-(4-nitrophenyl)-carbonate 12. Compound **11** (7.6 g; 32 mmol, 1.0 eq.) was dissolved in 100 ml CH₂Cl₂. 4-Nitrophenyl chloroformate (12.8 g; 64 mmol, 2.0 eq.) was added slowly to the reaction flask and the mixture was kept for 1 h at rt. Then, for consumption of the excess of chloroformate and for facilitation of purification, 7.5 ml tri(ethylene glycol) monomethyl ether (7.9 g, 48 mmol, 1.5 eq.) was added. After 20 min the solution was diluted with CH₂Cl₂ and washed with 1 M HCl. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed by evaporation. Column chromatography (petroleum ether 50–70/ethyl acetate 6:1 v/v). Yield: 6.8 g (17 mmol, 53%) colourless solid. TLC (PE/EE 6:1 v/v): R_f = 0.73; ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.38–8.33 (*m*, 2H), 7.73–7.67 (*m*, 2H), 7.43–7.36 (*m*, 4H), 4.73 (*s*, 2H), 0.91 (*s*, 9H), 0.09 (*s*, 6H); ¹³C-NMR (101 MHz, DMSO-*d*₆): δ 155.2, 150.7, 149.3, 145.4, 139.6, 127.2, 125.4, 122.7, 120.9, 63.6, 25.8, 18.0, –5.3; IR: 2,954, 2,929, 2,857, 1,768, 1,265 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₂₀H₂₅NO₆Si, 426.1349; found, 426.1340.

tert-Butylmethyl(2-(methylamino)ethyl)-carbamate 13. A flask containing 4.6 ml *N,N*-dimethylethylenediamine (3.7 g, 42 mmol, 3.8 eq.) in 40 ml CH₂Cl₂ was cooled to 0 °C. A solution of 2.4 g di-*tert*-butyl dicarbonate (11 mmol, 1.0 eq.) in 20 ml CH₂Cl₂ was added dropwise and, following the reaction mixture, was allowed to warm to rt. After 16 h, the solvent was removed in vacuum. The product was extracted with ethyl acetate/water (2:1 v/v) and washed with saturated aqueous NaHCO₃. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed by evaporation. Yield: 1.6 g (8.6 mmol, 78%) yellowish oil. ¹H-NMR (600 MHz, CDCl₃): δ 3.35–3.25 (*m*, 2H, rotamers), 2.85 (*s*, 3H), 2.70 (*t*, *J* = 6.7 Hz, 2H), 2.42 (*s*, 3H), 1.43 (*s*, 9H); ¹³C-NMR (151 MHz, CDCl₃): δ 156.1, 79.5, 49.8, 48.8 + 48.3 (rotamers), 36.4, 34.9 + 34.8 (rotamers), 28.6; IR: 2,974, 2,931, 1,687, 1,154 cm⁻¹; HRMS (ESI⁺, *m/z*): [M + Na]⁺ calcd. for C₉H₂₀N₂O₂, 211.1417; found, 211.1411.

4-(Hydroxymethyl)phenyl-methyl(2-(methylamino)ethyl)-carbamate 14. At 0 °C to a stirred solution of 1.6 g compound **13** (8.6 mmol, 1.2 eq.), 1.9 ml diisopropylethylamine (1.4 g, 11 mmol, 1.6 eq.) and catalytic amounts of 4-dimethylaminophenol in 30 ml toluene 2.8 g activated carbonate **12** (7.0 mmol, 1.0 eq.) was added. The reaction mixture was allowed to warm to rt and stirred for 16 h. The solution was diluted with ethyl acetate and washed with 1 M HCl, followed by saturated aqueous NaHCO₃. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed by evaporation. For deprotection the residue was redissolved in a mixture of CH₂Cl₂/trifluoroacetic acid (1:1 v/v). After 1 h the volatile components were removed by evaporation and the residue was co-evaporated twice with toluene. The crude material was purified by automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 1.6 g (6.9 mmol, 98%) yellowish oil. TLC (CH₂Cl₂/MeOH 4:1 v/v): R_f = 0.67; ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.72, 8.62 (br.s, 2H, rotamers), 7.34–7.28 (*m*, 2H), 7.14–7.07 (*m*, 2H), 4.48 (*s*, 2H), 3.69, 3.57 (*t*, *J* = 6.0 Hz, 2H, rotamers), 3.24–3.10 (*m*, 2H, rotamers), 3.05, 2.93 (*s*, 3H, rotamers), 2.68–2.57 (*m*, 3H, rotamers); ¹³C-NMR (101 MHz, DMSO-*d*₆): δ 154.7 + 153.8 (rotamers), 149.9, 139.7, 127.2, 121.7 + 121.4 (rotamers), 62.4,

Bis-(4-(dodecyl-ethan-1,2-diylbis(methylcarbamate))-oxybenzyl)-N,N-diisopropylaminophosphoramidite 5q. General procedure C with 0.15 g dichloro-N,N-diisopropylphosphoramidite (0.75 mmol, 1.0 eq.) dissolved in 3 ml THF, 0.24 ml triethylamine (0.17 g, 1.7 mmol, 2.3 eq.) and 0.71 g compound 15q (1.6 mmol, 2.1 eq.) in 5 ml THF. The crude product was purified using column chromatography (petroleum ether 50–70/ethyl acetate 1:1 v/v + 5% Et₃N): R_f = 0.50; 0.37 g (0.36 mmol, 48%) colourless oil. TLC (PE/EE 1:1 v/v + 5% Et₃N): R_f = 0.50; ¹H-NMR (600 MHz, CDCl₃): δ 7.36–7.30 (m, 4H), 7.08–7.03 (m, 4H), 4.76–4.62 (m, 4H), 4.11–4.02 (m, 4H), 3.73–3.62 (m, 2H), 3.61–3.42 (m, 8H, rotamers), 3.14–2.90 (m, 12H, rotamers), 1.67–1.56 (m, 4H, rotamers), 1.37–1.21 (m, 36H), 1.19 (d, J = 6.8 Hz, 12H), 0.87 (t, J = 6.9 Hz, 6H, rotamers); ¹³C-NMR (101 MHz, CDCl₃): δ 157.0, 154.7, 150.7 + 150.6 (rotamers), 136.6, 128.0 + 128.0 (d, J = 2.6 Hz), 121.6 + 121.5 (rotamers), 65.9 + 65.8 (rotamers), 65.0 (d, J = 18.3 Hz), 47.4 + 47.3 (rotamers), 46.9 + 46.4 (rotamers), 43.2 (d, J = 12.3 Hz), 35.4, 35.3 (rotamers), 35.0 + 34.6 (rotamers), 32.0, 29.8, 29.7, 29.7, 29.5, 29.4, 29.2 + 29.2 (rotamers), 26.1, 24.8 (d, J = 7.4 Hz), 22.8, 14.2; ³¹P-NMR (162 MHz, CDCl₃): δ 147.3; IR: 2,923, 2,853, 1,721, 1,699, 1,200 cm⁻¹; HRMS (ESI⁺, m/z): [M + H]⁺ calcd. for C₄₈H₈₀N₅O₁₀P, 1030.6982; found, 1030.6968.

5-Chloro-cycloSal-3'-deoxy-2',3'-didehydrothymidine monophosphate 7.

To a suspension of 0.50 g d4T 1 (2.2 mmol, 1.0 eq.) in 8 ml, acetonitrile was added 0.53 ml diisopropylethylamine (0.54 g, 3.1 mmol, 1.4 eq.) followed by 0.60 g 5-chlorosalicylchlorophosphate 8 (2.7 mmol, 1.2 eq.). The reaction mixture was stirred for 3 h and subsequently cooled to 0 °C. By addition of a 5.5-M solution of 0.57 ml tert-butylhydroperoxide in n-decane (3.1 mmol, 1.4 eq.) the phosphite was oxidized for 20 min. The solvent was removed in vacuum. The residue was redissolved in CH₂Cl₂ and washed with 1 M ammonium acetate solution. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed by evaporation. The crude product was purified using column chromatography (CH₂Cl₂/MeOH 9:1 v/v). Yield: 0.91 g (2.1 mmol, 97%) colourless foam as a mixture of two diastereomers. TLC (CH₂Cl₂/MeOH 9:1 v/v): R_f = 0.29; ¹H-NMR (500 MHz, CDCl₃): δ 8.92, 8.92 (br.s, 1H, diastereomers), 7.33–7.26 (m, 1H, ds), 7.20, 7.18 (s, 1H, ds), 7.12–7.07 (m, 1H, ds), 7.04–6.95 (m, 2H, ds), 6.40–6.32 (m, 1H, ds), 5.94, 5.94 (d, J = 5.8 Hz, ds), 5.43–5.18 (m, 2H, ds), 5.06–4.99 (m, 1H, ds), 4.47–4.30 (m, 2H, ds), 1.82, 1.73 (s, 3H, ds); ¹³C-NMR (126 MHz, CDCl₃): δ 163.9 + 163.8 (diastereomers), 150.9 + 150.8 (ds), 148.7 + 148.7 (ds), 135.8 + 135.6 (ds), 132.8 + 132.7 (ds), 130.3 + 130.3 (ds), 130.1 + 130.1 (ds), 128.1 + 128.0 (ds), 125.7 + 125.6 (ds), 122.3 + 122.3 (ds), 120.1 + 120.0 (d, J = 5.3 Hz, ds), 111.5 + 111.4 (ds), 90.0 + 89.9 (ds), 84.6 + 84.5 (ds), 68.7 + 68.6 (ds), 68.1 + 67.9 (d, J = 6.7 Hz, ds), 12.4 + 12.3 (ds); ³¹P-NMR (162 MHz, CDCl₃): δ -9.80, -9.87 (s, diastereomers); IR: 3,168, 3,050, 2,886, 1,684 cm⁻¹; HRMS (ESI⁺, m/z): [M + H]⁺ calcd. for C₁₇H₁₆ClN₂O₇P, 449.0276; found, 449.0287.

3'-Deoxy-2',3'-didehydrothymidinediphosphate 6 (d4TDP, tetra-n-butylammonium salt). cycloSal-triester 7 (1.1 g; 2.5 mmol, 1.0 eq.) was dissolved in 10 ml DMF and added dropwise to a solution of 2.1 g mono-(tetra-n-butylammonium)-phosphate (6.2 mmol, 2.5 eq.) in 12 ml DMF. After 16 h, the solvent was removed in vacuum. The residue was extracted with ethyl acetate/water followed by freeze-drying of the aqueous phase. The crude product was purified using automatic RP-18 chromatography (water/acetonitrile gradient: 5–100%, 0–90 min, flow 1 ml min⁻¹). The purification had to repeat for complete removal of the excess of the monophosphate salt. Yield: 0.78 g (0.90 mmol, 36%, 2 × Bu₄N⁺) colourless solid. TLC (isopropanol/NH₃/water 4:1:2.5 v/v/v): R_f = 0.16; ¹H-NMR (300 MHz, D₂O): δ 7.60 (d, J = 1.3 Hz, 1H), 6.93 (dt, J = 3.3 Hz, J = 1.7 Hz, 1H), 6.48 (dt, J = 6.2 Hz, J = 1.8 Hz, 1H), 5.91 (ddd, J = 6.1 Hz, J = 2.4 Hz, J = 1.4 Hz, 1H), 5.10–5.04 (m, 1H), 4.11 (dt, J = 6.2 Hz, J = 3.3 Hz, 2H), 3.25–3.05 (m, 16H), 1.86 (d, J = 1.3 Hz, 3H), 1.73–1.49 (m, 16H), 1.22 (sext, J = 7.4 Hz, 16H), 0.91 (t, J = 7.3 Hz, 24H); ¹³C-NMR (75 MHz, D₂O): δ 166.8, 152.2, 138.1, 134.2, 125.1, 111.2, 89.8, 85.8 (d, J = 8.5 Hz), 66.2 (d, J = 5.6 Hz), 58.0, 23.0, 19.0, 12.8, 11.4; ³¹P-NMR (162 MHz, D₂O): δ -8.32 (d, J = 21.7 Hz), -11.23 (d, J = 21.7 Hz); IR: 3,220, 1,645, 1,486 cm⁻¹; MALDI-MS (ESI⁺, m/z): [M-H]⁻ calcd. for C₁₀H₁₄N₂O₁₀P₂, 383.005; found, 382.928.

General procedure D: preparation of γ-bis(4-alkanoyloxybenzyl)-d4TTPs 3.

D4TDP 6 (1.0 eq.) were once co-evaporated with DMF and then dissolved in acetonitrile. Phosphoramidites 5 (1.7–2.0 eq.) were added and the solvent removed in vacuum quantitatively. The residue was redissolved in a minimum of acetonitrile or in a mixture of acetonitrile/THF (1:1), and the reaction was started by addition of a 0.25-M solution of DCI in acetonitrile (1.2–1.4 eq.). After stirring for 1 min the reaction was cooled to -10 °C, and a 5.5 M solution of t-BuOOH in n-decane (2.1–2.2 eq.) was added for oxidation. The mixture was stirred for 20 min and the volatile components were removed in vacuum. The reaction was monitored with HPLC. If the conversion of d4TDP was not complete, the procedure was repeated as described above. The crude products were purified by automatic RP-18 flash chromatography followed by an ion exchange to the ammonium form with Dowex 50WX8 cation exchange resin and a second RP-18 chromatography (3a–g, l–q). For elution water/acetonitrile (5–100%, 0–40 min, flow 1 ml min⁻¹) or water/THF gradients (5–80%, 0–40 min, flow 1 ml min⁻¹) were used. Product-containing

fractions were pooled and the organic solvent evaporated. The remaining aqueous solutions were freeze-dried and the desired product obtained as colourless solids.

γ-Bis-(4-acetyloxybenzyl)-d4TTP 3a (ammonium salt). General procedure D with 86 mg d4TDP 6 (99 μmol, 1.0 eq.), 92 mg 5a (0.20 mmol, 2.0 eq.), 0.55 ml 0.25 M solution of DCI in acetonitrile (0.14 mmol, 1.4 eq.), 40 μl 5.5 M solution of t-BuOOH in n-decane (0.22 mmol, 2.2 eq.) in 0.7 ml acetonitrile. The crude product was purified using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 46 mg (58 μmol, 59%) colourless solid. UV (HPLC): λ_{max} = 265 nm; HPLC: t_R = 11.00 min (method A); 8.75 min (method B); ¹H-NMR (400 MHz, CD₃OD): δ 7.67 (d, J = 1.3 Hz, 1H), 7.46–7.40 (m, 4H), 7.13–7.06 (m, 4H), 6.94 (dt, J = 3.4 Hz, J = 1.8 Hz, 1H), 6.48 (dt, J = 5.9 Hz, J = 1.9 Hz, 1H), 5.82 (dt, J = 5.9 Hz, J = 1.9 Hz, 1H), 5.18 (d, J = 8.1 Hz, 4H), 4.99–4.93 (m, 1H), 4.32–4.17 (m, 2H), 2.30 (s, 6H), 1.92 (d, J = 1.3 Hz, 3H); ¹³C-NMR (101 MHz, CD₃OD): δ 171.1, 166.5, 152.8, 152.3, 138.7, 134.9, 134.9 (d, J = 6.8 Hz), 130.4 (d, J = 2.7 Hz), 127.3, 122.9, 112.0, 90.8, 87.1 (d, J = 8.8 Hz), 70.3 (d, J = 6.1 Hz), 67.6, 20.9, 12.5; ³¹P-NMR (162 MHz, CD₃OD): δ -11.69 (d, J = 19.4 Hz), -13.11 (d, J = 17.1 Hz), -23.51 (t, J = 17.8 Hz); IR: 3,191, 2,988, 1,756, 1,687, 1,193 cm⁻¹; MALDI-MS (m/z): [M-H]⁻ calcd. for C₂₈H₃₁N₂O₁₇P₃, 759.076; found, 759.131.

γ-Bis-(4-propanoyloxybenzyl)-d4TTP 3b (ammonium salt). General procedure D with 87 mg d4TDP 6 (0.10 mmol, 1.0 eq.), 93 mg 5b (0.20 mmol, 2.0 eq.), 0.48 ml 0.25 M solution of DCI in acetonitrile (0.12 mmol, 1.2 eq.), 38 μl 5.5 M solution of t-BuOOH in n-decane (0.21 mmol, 2.1 eq.) in 0.5 ml acetonitrile. The crude product was purified using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 35 mg (43 μmol, 43%) colourless solid. UV (HPLC): λ_{max} = 265 nm; HPLC: t_R = 11.83 min (method A); 10.09 min (method B); ¹H-NMR (200 MHz, CD₃OD): δ 7.63 (d, J = 1.3 Hz, 1H), 7.44–7.32 (m, 4H), 7.09–6.99 (m, 4H), 6.90 (dt, J = 3.4 Hz, J = 1.6 Hz, 1H), 6.43 (dt, J = 5.9 Hz, J = 1.7 Hz, 1H), 5.77 (ddd, J = 5.9 Hz, J = 2.4 Hz, J = 1.4 Hz, 1H), 5.12 (d, J = 8.0 Hz, 4H), 4.94–4.89 (m, 1H), 4.31–4.08 (m, 2H), 2.58 (q, J = 7.5 Hz, 4H), 1.86 (d, J = 1.3 Hz, 3H), 1.20 (t, J = 7.5 Hz, 6H); ¹³C-NMR (75 MHz, CD₃OD): δ 174.5, 166.5, 152.8, 152.4, 138.7, 135.7, 134.9 (d, J = 7.6 Hz), 130.4 (d, J = 2.4 Hz), 127.2, 122.9, 112.0, 90.8, 87.2 (d, J = 9.0 Hz), 70.3 (d, J = 5.6 Hz), 67.6 (d, J = 6.3 Hz), 28.3, 12.5, 9.3; ³¹P-NMR (81 MHz, CD₃OD): δ -11.76 (d, J = 19.4 Hz), -13.19 (d, J = 17.1 Hz), -23.51 (t, J = 18.4 Hz); IR: 3,195, 2,987, 1,758, 1,691, 1,254 cm⁻¹; MALDI-MS (m/z): [M-H]⁻ calcd. for C₃₀H₃₅N₂O₁₇P₃, 787.108; found, 787.275.

γ-Bis-(4-pentanoyloxybenzyl)-d4TTP 3c (ammonium salt). General procedure D with 90 mg d4TDP 6 (0.10 mmol, 1.0 eq.), 0.11 g 5c (0.21 mmol, 2.0 eq.), 0.50 ml 0.25 M solution of DCI in acetonitrile (0.13 mmol, 1.2 eq.), 40 μl 5.5 M solution of t-BuOOH in n-decane (0.21 mmol, 2.1 eq.) in 0.5 ml acetonitrile. The crude product was purified using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 43 mg (49 μmol, 47%) colourless solid. UV (HPLC): λ_{max} = 265 nm; HPLC: t_R = 13.61 min (method A); ¹H-NMR (400 MHz, CD₃OD): δ 7.59 (d, J = 1.5 Hz, 1H), 7.38–7.32 (m, 4H), 7.04–6.97 (m, 4H), 6.87 (dt, J = 3.4 Hz, J = 1.7 Hz, 1H), 6.39 (dt, J = 5.9 Hz, J = 1.8 Hz, 1H), 5.77 (ddd, J = 5.9 Hz, J = 2.4 Hz, J = 1.4 Hz, 1H), 5.12 (d, J = 8.1 Hz, 4H), 4.94–4.84 (m, 1H), 4.26–4.08 (m, 2H), 2.57–2.50 (m, 4H), 1.84 (d, J = 1.5 Hz, 3H), 1.71–1.61 (m, 4H), 1.47–1.26 (m, 4H), 0.93 (t, J = 7.4 Hz, 6H); ¹³C-NMR (101 MHz, CD₃OD): δ 173.8, 166.5, 152.7, 152.3, 138.6, 135.6, 134.8 (d, J = 7.3 Hz), 130.5 (d, J = 3.1 Hz), 127.2, 122.9, 112.0, 90.8, 87.1 (d, J = 8.8 Hz), 70.4 (dd, J = 6.0 Hz, J = 2.1 Hz), 67.9 (d, J = 5.4 Hz), 34.7, 28.1, 23.2, 14.1, 12.5; ³¹P-NMR (81 MHz, CD₃OD): δ -11.76 (d, J = 19.3 Hz), -13.19 (d, J = 17.1 Hz), -23.51 (t, J = 18.2 Hz); IR: 3,183, 2,959, 1,755, 1,687, 1,219 cm⁻¹; MALDI-MS (m/z): [M-H]⁻ calcd. for C₃₄H₄₃N₂O₁₇P₃, 843.170; found, 843.267.

γ-Bis-(4-heptanoyloxybenzyl)-d4TTP 3d (ammonium salt). General procedure D with 99 mg d4TDP 6 (0.11 mmol, 1.0 eq.), 0.14 g 5d (0.23 mmol, 2.0 eq.), 0.55 ml 0.25 M solution of DCI in acetonitrile (0.14 mmol, 1.2 eq.), 44 μl 5.5 M solution of t-BuOOH in n-decane (0.24 mmol, 2.1 eq.) in 0.5 ml acetonitrile. The crude product was purified using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 41 mg (44 μmol, 40%) colourless solid. UV (HPLC): λ_{max} = 265 nm; HPLC: t_R = 15.40 min (method A); ¹H-NMR (400 MHz, CD₃OD): δ 7.68 (d, J = 1.2 Hz, 1H), 7.46–7.39 (m, 4H), 7.11–7.05 (m, 4H), 6.95 (dt, J = 3.4 Hz, J = 1.6 Hz, 1H), 6.48 (dt, J = 6.1 Hz, J = 1.7 Hz, 1H), 5.86–5.80 (m, 1H), 5.18 (d, J = 8.2 Hz, 4H), 5.01–4.94 (m, 1H), 4.34–4.16 (m, 2H), 2.60 (t, J = 7.4 Hz, 4H), 1.92 (d, J = 1.2 Hz, 3H), 1.76 (quint, J = 7.4 Hz, 4H), 1.51–1.34 (m, 12H), 0.96 (t, J = 6.8 Hz, 6H); ¹³C-NMR (101 MHz, CD₃OD): δ 173.8, 166.5, 152.8, 152.3, 138.4, 135.8, 134.9 (d, J = 7.8 Hz), 130.5 (d, J = 2.9 Hz), 127.2, 122.9, 112.1, 90.8, 87.2 (d, J = 8.9 Hz), 70.4 (d, J = 6.8 Hz), 67.9 (d, J = 4.9 Hz), 35.0, 32.7, 29.9, 23.6, 25.9, 14.4, 12.5; ³¹P-NMR (162 MHz, CD₃OD): δ -11.64 (br.s), -13.08 (d, J = 17.5 Hz), -23.47 (br.s); IR: 3,190, 2,928, 1,756, 1,689, 1,250 cm⁻¹; MALDI-MS (m/z): [M-H]⁻ calcd. for C₃₈H₅₁N₂O₁₇P₃, 899.233; found, 899.229.

γ-Bis-(4-nonanoyloxybenzyl)-d4TTP 3e (ammonium salt). General procedure D with 0.15 g d4TDP 6 (0.17 mmol, 1.0 eq.), 0.22 g 5e (0.34 mmol, 2.0 eq.), 0.88 ml 0.25 M solution of DCI in acetonitrile (0.22 mmol, 1.3 eq.), 68 μl 5.5 M solution of t-BuOOH in n-decane (0.37 mmol, 2.2 eq.) in 3 ml acetonitrile. The crude product

(HPLC grade) and frozen in liquid nitrogen followed by defrosting, ultrasonication, centrifugation, filtration and stored as described for (b).

Samples were defrosted and 50–80 μl were subjected to HPLC analysis. The calculation of $t_{1/2}$ was performed analogously to that for the chemical hydrolysis studies.

Enzyme-catalysed hydrolysis of TriPPPro-d4TTP compounds 3a–n and intermediates 4a,e,j in CEM cell extracts. A volume of 10 μl of the appropriate 50 mM DMSO- d_6 stock solution was diluted to 6.0 mM hydrolysis solution by addition of 73.3 μl DMSO- d_6 . Seven different samples including 10 μl water and 10 μl hydrolysis solution were prepared. The reaction was started by addition of 50 μl human CEM cell extract and the mixture was incubated at 37 °C for different time periods of hydrolysis. The work-up depended on the particular compound: (a) for 3a–f,i,m,p and 4a,e the reactions were stopped by addition of 150 μl MeOH. The solution was kept on ice for 5 min followed by centrifugation for 5 min (13,000 r.p.m.). The supernatants were filtered (Chromafil RC-20/15 MS, 0.2 μm) and stored in liquid nitrogen. (b) For 3g–i,k,n and 4j, the samples were directly frozen in liquid nitrogen. The solution was defrosted followed by ultrasonication for 10 min. After centrifugation for 5 min the supernatants were filtered (Chromafil AO-20/3, 0.2 μm) and stored at –196 °C. (c) For 3j the mixture was diluted with 70 μl THF (HPLC grade) and frozen in liquid nitrogen followed by defrosting, ultrasonication, centrifugation, filtration and stored as described for (b). Samples were defrosted and 50–80 μl were subjected to HPLC analysis. The calculation of $t_{1/2}$ was performed analogously to that for the chemical hydrolysis studies.

Preparation of cell extracts. Human CD4⁺ T-lymphocyte CEM cells were grown in RPMI-1640-based cell culture medium to a final density of $\sim 3 \times 10^6$ cells ml^{-1} . Then, cells were centrifuged for 10 min at 1,250 r.p.m. at 4 °C, washed twice with cold PBS and the pellet was resuspended at 10^8 cells ml^{-1} and sonicated (Hielscher Ultrasound Techn., 100% amplitude, three-times for 10 s) to destroy cell integrity. The resulting cell suspension was then centrifuged at 10,000 r.p.m. to remove cell debris, and the supernatant divided into aliquots before being frozen at –80 °C and used.

Anti-HIV activity assay. Inhibition of HIV-1(III_B)- and HIV-2(ROD)-induced cytopathicity in wild-type CEM/0 and TK-deficient CEM/TK[–] cell cultures was measured in microtitre 96-well plates containing $\sim 3 \times 10^5$ CEM cells ml^{-1} infected with 100 CCID₅₀ of HIV per millilitre and containing appropriate dilutions of the test compounds. After 4–5 days of incubation at 37 °C in a CO₂-controlled humidified atmosphere, CEM giant (syncytium) cell formation was examined microscopically. The EC₅₀ (50% effective concentration) was defined as the compound concentration required to inhibit HIV-induced giant cell formation by 50%.

Primer extension reactions. The used polymerase HIV RT was obtained from Roboklon. The primer and template were purchased from Life Technologies.

Primer sequence:

5'-TTGGATAGGAGGAAGTCTCGGTTGC-3'

Template sequence:

5'-AGACAAACCTATCTCCTTCAGGACCAACG-3'

The primer extension assays were performed under the following conditions:

The primer was labelled using [γ -³²P]-ATP according to standard techniques.

After 5-min incubation at 95 °C in 20 mM Tris-HCl (pH 7.6) and 50 mM NaCl, the hybridization/annealing of the primer to the template strand was achieved by a cooling phase from 95 to 20 °C over 3 h. The final assay solution (20 μl) consists of 2.5 μM dNTPs or hydrolysate, 1 \times reaction buffer (50 mM Tris-HCl (pH 8.6), 10 mM MgCl₂ and 40 mM KCl), 0.02 μM of hybridization and 0.2 units of the enzyme, which was incubated at 37 °C for 10 min. The reaction was stopped by heating up to 80 °C for 3 min. The assays were separated using a denaturing PAGE (15%). The results were visualized by phosphorimaging.

References

- Jordheim, L. P., Durantel, D., Zoulim, F. & Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. *Nat. Rev. Drug Discov.* **12**, 447–464 (2013).
- Deval, J. Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. *Drugs* **69**, 151–166 (2009).
- Chilar, T. & Ray, A. S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. *Antiviral Res.* **85**, 39–58 (2010).
- El Safadi, Y., Vivet-Boudou, V. & Marquet, R. HIV-1 reverse transcriptase inhibitors. *Microbiol. Biotechnol.* **75**, 723–737 (2007).
- Burton, J. R. & Everson, G. T. HCV NS5B polymerase inhibitors. *Clin. Liver Dis.* **13**, 453–465 (2009).
- De Clercq, E. Antiviral drugs in current clinical use. *J. Clin. Virol.* **30**, 115–133 (2004).
- Schader, S. M. & Wainberg, M. A. Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future. *HIV AIDS Rev.* **10**, 91–98 (2011).
- Balzarini, J., Herdewijn, P. & De Clercq, E. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. *J. Biol. Chem.* **264**, 6127–6133 (1989).
- Ho, H.-T. & Hitchcock, M. J. M. Cellular pharmacology of 2',3'-Dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. *Antimicrob. Agents Chemother.* **33**, 344–349 (1987).
- Balzarini, J. *et al.* The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine are highly dependent on the cell species. *Biochem. Pharmacol.* **37**, 2065–2068 (1988).
- McKenna, C. E., Kashemirov, B. A., Peterson, L. W. & Goodman, M. F. Modifications to the dNTP triphosphate moiety: from mechanistic probes for DNA polymerases to antiviral and anti-cancer drug design. *Biochim. Biophys. Acta* **1804**, 1223–1230 (2010).
- Freeman, S. & Ross, K. C. Prodrug design for phosphates and phosphonates. *Prog. Med. Chem.* **34**, 112–142 (1997).
- Van Rompay, A. R., Johansson, M. & Karlsson, A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. *Pharmacol. Ther.* **87**, 189–198 (2000).
- Meier, C., Knispel, T., De Clercq, E. & Balzarini, J. CycloSal-Pro-nucleotides (cycloSal-NMP) of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxy-2',3'-didehydroadenosine (d4A): synthesis and antiviral evaluation of a highly efficient delivery system. *J. Med. Chem.* **42**, 1604–1614 (1999).
- Meier, C., Lomp, A., Meerbach, A. & Wutzler, P. CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV. *J. Med. Chem.* **45**, 5157–5172 (2002).
- Wagner, C. R., Iyer, V. V. & McIntee, E. J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. *Med. Res. Rev.* **20**, 417–451 (2000).
- Mutahir, Z. *et al.* Thymidine kinase 1 regulatory fine-tuning through tetramer formation. *FEBS J.* **280**, 1531–1541 (2013).
- Hecker, S. J. & Erion, M. D. Prodrugs of phosphates and phosphonates. *J. Med. Chem.* **51**, 2328–2345 (2008).
- Pradere, U., Garnier-Amblard, E. C., Coats, S. J., Amblard, F. & Schinazi, R. F. Synthesis of nucleoside phosphate and phosphonate prodrugs. *Chem. Rev.* **114**, 9154–9218 (2014).
- Ho, H.-T. & Hitchcock, J. M. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. *Antimicrob. Agents Chemother.* **33**, 844–849 (1989).
- Zhang, Y., Gao, Y., Wen, X. & Ma, H. Current strategies for improving oral absorption of nucleoside analogues. *Asian J. Pharm. Sci.* **9**, 65–74 (2014).
- Cahard, D., McGuigan, C. & J. Balzarini, J. Aryloxyphosphoramidate triesters as pro-tides. *Mini Rev. Med. Chem.* **4**, 371–381 (2004).
- Meier, C. & Balzarini, J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. *Antiviral Res.* **71**, 282–292 (2006).
- Meier, C. CycloSal phosphates as chemical trojan horses for intracellular nucleotide and glycosylmonophosphate delivery-chemistry meets biology. *Eur. J. Org. Chem.* **5**, 1081–1102 (2006).
- Meier, C., Lorey, M., De Clercq, E. & Balzarini, J. CycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. *J. Med. Chem.* **41**, 1417–1427 (1998).
- Jessen, H. J., Balzarini, J. & Meier, C. Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters. *J. Med. Chem.* **51**, 6592–6598 (2008).
- Gisch, N., Balzarini, J. & Meier, C. Doubly loaded cycloSaligenyl-pronucleotides. 5,5'-Bis(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates). *J. Med. Chem.* **52**, 3464–3473 (2009).
- Krylov, I. S., Kashemirov, B. A., Hilfinger, J. M. & McKenna, C. E. Evolution of an amino acid based prodrug approach: stay tuned. *Mol. Pharm.* **10**, 445–458 (2013).
- Furman, P. A. *et al.* Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. *Proc. Natl Acad. Sci. USA* **83**, 8333–8337 (1986).
- Törnevik, Y., Ullman, B., Balzarini, J., Wahren, B. & Eriksson, S. Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. *Biochem. Pharmacol.* **49**, 829–837 (1995).
- Mackman, R. L. *et al.* Synthesis and anti-HIV activity of cyclic pyrimidine phosphonothioxy nucleosides and their prodrugs: a comparison of phosphonates and corresponding nucleosides. *Nucleosides Nucleotides Nucleic Acids* **26**, 573–577 (2007).
- Jessen, H. J., Schulz, T., Balzarini, J. & Meier, C. Bioreversible protection of nucleoside diphosphates. *Angew. Chem. Int. Ed. Engl.* **47**, 8719–8722 (2008).
- Schulz, T., Balzarini, J. & Meier, C. The DiPPro approach: synthesis, hydrolysis, and antiviral activity of lipophilic d4T diphosphate prodrugs. *ChemMedChem* **9**, 762–775 (2014).

34. Pertenbreiter, F., Balzarini, J. & Meier, C. Nucleoside mono- and diphosphate prodrugs of 2',3'-dideoxyuridine and 2',3'-dideoxy-2',3'-didehydrouridine. *ChemMedChem*. **10**, 94–106 (2015).
35. Weinschenk, L., Schols, D., Balzarini, J. & Meier, C. Nucleoside diphosphate prodrugs: non-symmetric DiPPro-nucleotides. *J. Med. Chem.* **58**, 6114–6130 (2015).
36. Sienaert, R. *et al.* Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. *Mol. Pharmacol.* **61**, 249–254 (2002).
37. Tan, X., Chu, C. K. & Boudinot, F. D. Development and optimization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. *Adv. Drug Deliv. Rev.* **39**, 117–151 (1999).
38. Bonnaffé, D., Dupraz, B., Ughetto-Monfrin, J., Namane, A. & Dinh, T. H. Synthesis of acyl pyrophosphates - application to the synthesis of nucleotide lipophilic prodrugs. *Tetrahedron Lett.* **36**, 531–534 (1995).
39. Kreimeyer, A., André, F., Gouyette, C. & Dinh, T. H. Transmembrane transport of adenosine 5'-triphosphate using a lipophilic cholesteryl derivative. *Angew. Chem. Int. Ed. Engl.* **37**, 2853–2855 (1998).
40. Kumar, S. *et al.* Terminal phosphate labeled nucleotides: synthesis, applications, and linker effect on incorporation by DNA polymerases. *Nucleosides Nucleotides Nucleic Acids* **24**, 401–408 (2005).
41. Sood, A. *et al.* Terminal phosphate-labeled nucleotides with improved substrate properties for homogeneous nucleic acid assays. *J. Am. Chem. Soc.* **127**, 2394–2395 (2005).
42. Vinogradov, S. V., Kohli, E. & Zeman, A. D. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates. *Pharm. Res.* **23**, 920–930 (2006).
43. Galmarini, C. M. *et al.* Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. *Mol. Cancer Ther.* **7**, 3373–3380 (2008).
44. Peters, G. J., Adema, A. D., Bijnsdorp, I. V. & Sandvold, M. L. Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. *Nucleosides Nucleotides Nucleic Acids* **30**, 1168–1180 (2011).
45. Menger, F. M., Guo, Y. & Lee, A. S. Synthesis of a lipid peptide drug conjugate N-4-(acylpeptidyl)-ara-C. *Bioconjugate Chem.* **5**, 162–166 (1994).
46. Ibrahim, S. S., Boudinot, F. D., Schinazi, R. F. & Chu, C. K. Physicochemical properties, bioconversion and disposition of lipophilic prodrugs of 2',3'-dideoxycytidine. *Antiviral Chem. Chemother.* **7**, 167–172 (1996).
47. Horwitz, J. P., Chua, J., Da Rooge, M. A., Noel, M. & Klundt, I. L. Nucleosides. IX. The formation of 2',2'-unsaturated pyrimidine nucleosides via a novel beta-elimination reaction. *J. Org. Chem.* **31**, 205–211 (1966).
48. Warnecke, S. & Meier, C. Synthesis of nucleoside di- and triphosphates and dinucleoside polyphosphates with cycloSal-nucleotides. *J. Org. Chem.* **74**, 3024–3030 (2009).
49. DeWit, M. W. & Gillies, E. R. A cascade biodegradable polymer based on alternating cyclization and elimination reactions. *J. Am. Chem. Soc.* **131**, 18327–18334 (2009).
50. Bonnaffé, D., Dupraz, B., Ughetto-Monfrin, J., Namane, A. & Dinh, T. H. Potential lipophilic nucleotide prodrugs- synthesis, hydrolysis and antiviral activity of AZT and d4T acyl nucleotides. *J. Org. Chem.* **61**, 895–902 (1996).
51. Sarac, I. & Meier, C. Efficient automated solid-phase synthesis of DNA and RNA 5'-triphosphates. *Chem. Eur. J.* **21**, 1–7 (2015).
52. Tonn, V. C. & Meier, C. Solid-phase synthesis of (Poly)phosphorylated Nucleosides and conjugates. *Chem. Eur. J.* **17**, 9832–9842 (2011).
53. Wolf, S., Zismann, T., Lunau, N. & Meier, C. Reliable synthesis of various nucleoside diphosphate glycopyranoses. *Chem. Eur. J.* **15**, 7656–7664 (2009).

Acknowledgements

We are grateful to Lizette van Berckelaer, Ria Van Berwaer, Kristien Minner, Sandra Claes and Evelyne Van Kerckhove for excellent technical assistance. The work conducted by C.M. has been supported by the Deutsche Forschungsgemeinschaft (DFG; Me1161/13-1) and that of D.S. and J.B. has been supported by the KU Leuven (GOA 15/19 TBA).

Author contributions

C.M. headed the project; T.G. performed the chemical synthesis; T.D.d.O. contributed with the biochemical assays and D.S. and J.B. carried out the antiviral testing of the synthesized compounds. All authors were involved in the preparation of the manuscript.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Gollnest, T. *et al.* Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals. *Nat. Commun.* **6**:8716 doi: 10.1038/ncomms9716 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>